Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 704

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 704
---
 thereby terminating MultiplAI Health Ltd,’s participation in the Business Combination Agreement dated March 25, 2024. Subsequently, OmnigenicsAI Corp signed a notice of termination. This decision was made following a detailed evaluation of the financial and operational risks inherent in the integration process, as well as the recent regulatory changes issued by the U.S. FDA in May 2024 concerning Laboratory Developed Tests (LDTs), which directly impacted MultiplAI Health Ltd.’s compliance and market strategy in the U.S.. The termination of the SPA is intended to safeguard the strategic interests of Heritas Ltd., OmnigenicsAI Corp, and their shareholders. Upon execution of this termination agreement, all rights and obligations outlined in the SPA and related transaction documents ceased, ensuring the protection of the involved parties’ interests and compliance with any residual obligations under the Business Combination Agreement. On August 8, 2024, OmnigenicsAI Corp, Heritas Ltd., and MultiplAI Health Ltd. signed a binding term sheet outlining the terms and conditions for a Reseller License Agreement to settle MultiplAI Ltd.’s outstanding debt to Heritas Ltd,, amounting to US$395,260, due by February 2025. As part of the agreement, MultiplAI Ltd. will grant OmnigenicsAI Corp, exclusive rights to commercialize its proprietary blood -basedscreening tests in Latin America, along with providing 600 pre -paidtests for business development purposes. These exclusive rights are granted for a period of five years, commencing on January 1, 2025. Shared-based incentives In October 2024, Heritas Ltd., at the sole discretion of the shareholders of Heritas Ltd., entered into Deferred Share Right Agreements (“DSRs”) with three key employees of Heritas Argentina (referred to as the “Key Employee”, on an individual basis). These agreements were structured to incentivize and retain critical talent identified as essential for the Group’s success following the Closing. F-159 Notes to Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 22.Events after the reporting period (cont.) Under the terms of these DSRs, (i) each employee will receive a deferred share grant of 30,000shares of Heritas Ltd. (the “Shares”), for a total of 90,000shares to be granted; (ii) the Shares will vest and be transferred one year after the Closing (the “Vesting Date”), provided the Key Employee remains employed with Heritas Ltd